Hyperlipidemia associated with HIV protease inhibitor use: Pathophysiology, prevalence, risk factors and treatment

Scandinavian Journal of Infectious Diseases

Volumn 32, Issue 2, 2000, Pages 111-123

  Penzak, S R ^a   Chuck, S K ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; COLESTIPOL; COLESTYRAMINE; EFAVIRENZ; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; METFORMIN; MEVINOLIN; NELFINAVIR; NEVIRAPINE; NICOTINIC ACID; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; SIMVASTATIN; TRIACYLGLYCEROL; TROGLITAZONE; VIRUS ENZYME;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG ELIMINATION; DRUG USE; FEMALE; FLUSHING; GLUCOSE INTOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIVER TOXICITY; MALE; MYOPATHY; PANCREATITIS; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RISK FACTOR;

EID: 0033873920     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655400750045196     Document Type: Review

References (72)

1. Protease inhibitors for the treatment of human immunodeficiency virus infection
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
3. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
4. Protease inhibitor-induced lipodystrophy
5. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome
6. Hypertriglyceridemia in the acquired immunodeficiency syndrome
7. Lipids, lipoproteins, and apoproteins in serum during infection
8. Serum lipids in viral and bacterial meningitis
9. Changes in serum lipoprotein pattern induced by acute infections
10. Circulating interferon-α levels and hypertriglyceridemia in the acquired immunodeficiency syndrome
11. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome
12. Increased De Novo Hepatic lipogenesis in human immunodeficiency virus infection
13. Plasma lipids in HIV-infected patients: A prospective study in 95 patients
14. Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex
15. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance
16. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro
17. Indinavir enhances retinoic acid signaling nelfinavir, saquinavir, and ritonavir inhibit retinoid effects in vitro
18. The LDL-receptor-related protein - Portrait of a multifunctional receptor
19. Are the decreased lipolytic enzyme activities responsible for the hypertriglyceridemia in PT-treated patients?
20. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, and inhibitor of HIV-1 protease
21. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors
22. Indinavir-associated lipodystrophy
23. Marked hyperlipidemia on ritonavir therapy
24. Clinical investigation of the incidence and severity of elevated cholesterol (CH) and triglycerides (TG) in AIDS patients receiving protease inhibitor (PI) therapy
25. Incidence of avascular necrosis of the hip in HIV-infected individuals on HAART
26. Screening for hyperglycemia and hyperlipidemia in HIV-infected persons receiving protease inhibitors
27. The incidence of hyperlipidemia with protease inhibitors (PI)
28. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1 + patients
29. Investigation of protease inhibitor-associated hypercholesterolemia in a University-based HIV clinic
30. Change in weight, body composition, and serum lipids prior to and after initiation of protease inhibitors
31. Incidence and factors associated with the development of hypercholesterolemia and hyperglycemia in HIV-infected patients using a protease inhibitor
32. Safety and efficacy of a combination of ritonavir and saquinavir added to AZT + 3TC in HIV infected patients
33. Associated lipodystrophy metabolic disorders due to protease inhibitor containing regimens
34. Significant increases in serum cholesterol are seen among HIV patients taking protease inhibitors
35. Reversal of hyperlipidemia in patients switching therapy to nelfinavir
36. Lipid abnormalities associated with use of protease inhibitors: Prevalence, clinical sequelae and treatment
37. Changes in body habitus in HIV(+) women after initiation of protease inhibitor therapy
38. Metabolic changes in HIV-infected patients treated with protease inhibitors
39. The effects of antiretroviral protease inhibitors (Pis) on serum lipids and glucose in HIV-infected patients
40. Serum lipid changes in HIV-infected patients under combination therapy containing a protease inhibitor
41. Chronic use of protease inhibitors is associated with hormonal abnormalities in otherwise healthy adult HIV-1 infected individuals
42. Evidence of unique metabolic effects of protease inhibitors
43. Hypercholesterolemia in children treated with HIV protease inhibitors
44. Effects of protease inhibitor use on hyperglycemia and hyperlipidemia: A five year analysis
45. Prevalence and risk factors for hyperglycemia, dyslipidemia, and coronary disease among HIV-infected patients on initial protease inhibitor therapy
46. Dyslipidemia and insulin resistance in HIV-infected patients treated with reverse transcriptase inhibitors alone and in combination with protease inhibitors
47. Changes in serum cholesterol and triglyceride levels in patients treated with indinavir or NRTIs
48. Women first: Durable response with dual protease inhibitor therapy without significant elevations in lipids
49. Reversibility of protease inhibitor (PI) lipodystrophy syndrome on stopping PIs or switching to nelfinavir
50. Hyperlipidemia
51. Triglycerides as a risk factor for coronary artery disease
52. National Cholesterol Education Program: Second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
53. Do protease inhibitors increase the risk for coronary heart disease among HIV positive patients?
54. No association observed between indinavir therapy for HIV-AIDS and myocardial infarction in 4 clinical trilas with 2,825 subjects
55. Increased morbidity from severe coronary heart disease in HIV-patients receiving protease inhibitors
56. A multi-center, randomized, open-label, comparative trial of the clinical benefit of switching the protease inhibitor (PI) by nevirapine (NVP) in HAART-experienced patients suffering from lipodystrophy (LD)
57. Management of indinavir-associated metabolic changes by substitution with efavirenz in virologically controlled HIV + persons
58. Reversion of lipodystrophy after switching HIV-1 protease inhibitors to nevirapine
59. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities
60. Metabolism and drug interactions of 3-hydroxy-3-methyl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar
61. The Medical Letter on drugs and therapeutics
62. Granneman. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
63. Clinical Pharmacokinetics of fibric acid derivatives (fibrates)
64. Overview of fenofibrate
65. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole
66. Myolysis and acute renal failure in a heart-transplant patient receiving lovastatin
67. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients
68. Effects of the PPAR-(gamma) activator troglitazone on protease inhibitor associated peripheral insulin resistance
69. The effect of recombinant human growth hormone on protease-inhibitor-associated fat maldistribution syndrome
70. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor (PI) therapy